テキサスにおける脂肪肝の臨床試験
テキサス内の拠点で、脂肪肝に関する20件の研究が参加者を募集しています。
テキサス内の都市
- San Antonio17件の研究
- Austin13件の研究
- Houston13件の研究
- Dallas9件の研究
- Brownsville7件の研究
- Round Rock7件の研究
- Sugar Land6件の研究
- Fort Worth6件の研究
- Arlington6件の研究
- Waco6件の研究
- Grand Prairie5件の研究
- Edinburg4件の研究
- Pasadena4件の研究
- Carrollton4件の研究
- The Woodlands4件の研究
- Lewisville3件の研究
- Corpus Christi3件の研究
- League City3件の研究
公式研究テキスト（英語）
A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
- GSK Investigational Site, Arlington
- GSK Investigational Site, Austin
- GSK Investigational Site, Bellaire
- 他5件
被験者募集中第3相
18歳〜75歳 · 全性別 · 2026/09/30更新 · NCT07704892A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
- GSK Investigational Site, Arlington
- GSK Investigational Site, Austin
- GSK Investigational Site, Bellaire
- 他4件
被験者募集中第3相
18歳〜75歳 · 全性別 · 2026/09/30更新 · NCT07701993A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD
- American Research Corporation, Austin
- Advanced Medical Trials, Georgetown
- American Research Corporation at The Texas Liver Institute, San Antonio
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/09/29更新 · NCT07527910A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
- American Research Corporation, Austin
- Pinnacle Clinical Research - Austin, Austin
- Methodist Dallas Medical Center, Dallas
- 他5件
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/09/25更新 · NCT05519475A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- IMA Clinical Research Austin, Austin
- American Research Corporation, Austin
- Pinnacle Clinical Research, Austin
- 他26件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07165028A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- Akero Clinical Study Site, Arlington
- Akero Clinical Study Site, Austin
- Akero Clinical Study Site, Austin
- 他28件
被験者募集中第3相
18歳〜80歳 · 全性別 · 2026/09/21更新 · NCT06528314A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
- GSK Investigational Site, Austin
- GSK Investigational Site, Austin
- GSK Investigational Site, Brownsville
- 他12件
被験者募集中第3相
18歳〜75歳 · 全性別 · 2026/09/17更新 · NCT07221188A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
- Pinnacle Clinical Research, Austin
- Bellaire Clinical Research, Bellaire
- South Texas Research Institute (STRI) - Brownsville, Brownsville
- 他14件
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/09/09更新 · NCT07288138A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- 89bio Clinical Study Site, Amarillo
- 89bio Clinical Study Site, Austin
- 89bio Clinical Study Site, Austin
- 他30件
被験者募集中第3相
18歳〜80歳 · 全性別 · 2026/09/03更新 · NCT06318169A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- 89bio Clinical Study Site, Amarillo
- 89bio Clinical Study Site, Austin
- 89bio Clinical Study Site, Austin
- 他21件
被験者募集中第3相
18歳〜75歳 · 全性別 · 2026/09/03更新 · NCT06419374Quantifying Hepatic Mitochondrial Fluxes in Humans
- Texas Diabetes Institute - University Health System, San Antonio
- University of Texas Health Science Center at San Antonio, San Antonio
被験者募集中第4相
18歳〜80歳 · 全性別 · 2026/08/17更新 · NCT05305287A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
- GSK Investigational Site, Arlington
- GSK Investigational Site, Austin
- GSK Investigational Site, Dallas
- 他4件
被験者募集中第2相
18歳〜70歳 · 全性別 · 2026/08/03更新 · NCT06613698A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
- GSK Investigational Site, Arlington
- GSK Investigational Site, Austin
- GSK Investigational Site, Austin
- 他16件
被験者募集中第3相
18歳〜75歳 · 全性別 · 2026/07/27更新 · NCT07221227A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
- GSK Investigational Site, Austin
- GSK Investigational Site, Austin
- GSK Investigational Site, Austin
- 他10件
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/07/08更新 · NCT06920043A Study of Efimosfermin Alfa in Adults With Hepatic Impairment
- GSK Investigational Site, San Antonio
被験者募集中第1相
18歳〜70歳 · 全性別 · 2026/06/09更新 · NCT07358546Evaluating the Pharmacokinetics and Safety of Miricorilant
- Site# 433, San Antonio
被験者募集中第1相
18歳〜75歳 · 全性別 · 2026/05/26更新 · NCT07553663Exploratory Analysis of Enhanced Liver Function (ELF) Test to Detect Early Fatty Liver in High Risk Population
- Methodist Dallas Medical Center, Dallas
被験者募集中観察研究
18歳以上 · 全性別 · 2026/05/13更新 · NCT06225193A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
- Pioneer Research Solutions, Houston
被験者募集中第1/2相健康なボランティア歓迎
18歳〜75歳 · 全性別 · 2026/04/16更新 · NCT05648214NAFLD Clinical Care Pathway
- Michael E. DeBakey VA Medical Center, Houston, TX, Houston
被験者募集中健康なボランティア歓迎
18歳以上 · 全性別 · 2025/11/14更新 · NCT06671886Evaluation of Non-Invasive Tests for Metabolic Liver Disease
- First Surgical Hospital, Bellaire
- Endeavor Clinical Trials, San Antonio
被験者募集中観察研究
18歳〜75歳 · 全性別 · 2025/08/14更新 · NCT07122700ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。